{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:30:19Z","timestamp":1790512219014,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1016\/j.vaccine.2005.11.037","type":"journal-article","created":{"date-parts":[[2005,12,8]],"date-time":"2005-12-08T12:14:25Z","timestamp":1134044065000},"page":"176-184","source":"Crossref","is-referenced-by-count":68,"title":["Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya"],"prefix":"10.1016","volume":"25","author":[{"given":"Jos\u00e9 A.","family":"Stoute","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joash","family":"Gombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Withers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joram","family":"Siangla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"McKinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Onyango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Milman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine","family":"Soisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. Ann","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Lyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelina","family":"Angov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Leach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent E.","family":"Kester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian F.","family":"Ockenhouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn A.","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carter L.","family":"Diggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Wittes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"D.","family":"Gray Heppner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2005.11.037_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4269\/ajtmh.2001.64.1","article-title":"Ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden","volume":"64","author":"Breman","year":"2001","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2005.11.037_bib2","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/bmj.328.7448.1086","article-title":"Roll back malaria: a failing global health campaign","volume":"328","author":"Yamey","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2005.11.037_bib3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4269\/ajtmh.1991.45.65","article-title":"Age-dependent acquired protection against Plasmodium falciparum in people having 2 years exposure to hyperendemic malaria","volume":"45","author":"Baird","year":"1991","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2005.11.037_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399498000179","article-title":"Clinical disease, immunity and protection against Plasmodium falciparum malaria in populations living in endemic area","author":"Hviid","year":"1998","journal-title":"Expert Rev Mol Med"},{"key":"10.1016\/j.vaccine.2005.11.037_bib5","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/415680a","article-title":"The economic and social burden of malaria","volume":"415","author":"Sachs","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2005.11.037_bib6","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/0169-4758(93)90130-8","article-title":"The major merozoite surface protein as a malaria vaccine target","volume":"9","author":"Diggs","year":"1993","journal-title":"Parasitol Today"},{"key":"10.1016\/j.vaccine.2005.11.037_bib7","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1098\/rstb.1984.0117","article-title":"Protective antigens of rodent and human bloodstage malaria","volume":"307","author":"Holder","year":"1984","journal-title":"Phil Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.vaccine.2005.11.037_bib8","doi-asserted-by":"crossref","first-page":"895","DOI":"10.4049\/jimmunol.138.3.895","article-title":"Monoclonal antibody characterization of the 195-kDa major surface glycoprotein of Plasmodium falciparum malaria schizonts and merozoites: identification of additional processed products and a serotype-restricted repetitive epitope","volume":"138","author":"Lyon","year":"1987","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2005.11.037_bib9","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0166-6851(92)90228-C","article-title":"Secondary processing of the Plasmodium falciparum merozoite surface protein-1 (MSP1) by a calcium-dependent membrane-bound serine protease: shedding of MSP133 as a noncovalently associated complex with other fragments of the MSP1","volume":"50","author":"Blackman","year":"1992","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.vaccine.2005.11.037_bib10","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1128\/IAI.72.3.1557-1567.2004","article-title":"Fine specificity of serum antibodies to Plasmodium falciparum merozoite surface protein, PfMSP-1(19), predicts protection from malaria infection and high-density parasitemia","volume":"72","author":"Okech","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2005.11.037_bib11","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/infdis\/173.3.765","article-title":"Clinical immunity to Plasmodium falciparum malaria is associated with antibodies to the 19-kDa C-terminal fragment of the merozoites surface antigen, PfMSP-1","volume":"173","author":"Egan","year":"1996","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2005.11.037_bib12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1046\/j.1365-3024.1999.00209.x","article-title":"Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro","volume":"21","author":"Egan","year":"1999","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.vaccine.2005.11.037_bib13","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1073\/pnas.012590199","article-title":"A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum","volume":"99","author":"Stowers","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2005.11.037_bib14","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1128\/IAI.69.3.1536-1546.2001","article-title":"Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial","volume":"69","author":"Stowers","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2005.11.037_bib15","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1128\/IAI.73.1.287-297.2005","article-title":"The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites","volume":"73","author":"Darko","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2005.11.037_bib16","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0166-6851(03)00077-X","article-title":"Development and pre-clinical analysis of a Plasmodium falciparum merozoite surface protein-1(42) malaria vaccine","volume":"128","author":"Angov","year":"2003","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.vaccine.2005.11.037_bib17","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1016\/j.vaccine.2004.07.023","article-title":"Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum","volume":"22","author":"Pichyangkul","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2005.11.037_bib18","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1016\/j.vaccine.2005.11.028","article-title":"Phase 1 safety and immunogenicity trial of FMP1\/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine","volume":"24","author":"Ockenhouse","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2005.11.037_bib19","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/jmedent\/27.4.570","article-title":"Characterization of malaria transmission by Anopheles (Diptera: Culicidae) in western Kenya in preparation for malaria vaccine trials","volume":"27","author":"Beier","year":"1990","journal-title":"J Med Entomol"},{"key":"10.1016\/j.vaccine.2005.11.037_bib20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0166-6851(95)00102-7","article-title":"Sequence heterogeneity of the C-terminal Cys-rich region of the merozoite surface protein-1 (MSP-1) in field samples of Plasmodium falciparum","volume":"73","author":"Kang","year":"1995","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.vaccine.2005.11.037_bib21","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/00062752-200303000-00002","article-title":"Malaria and anemia","volume":"10","author":"Ekvall","year":"2003","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.vaccine.2005.11.037_bib22","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1086\/367712","article-title":"Loss of red blood cell-complement regulatory proteins and increased levels of circulating immune complexes are associated with severe malarial anemia","volume":"187","author":"Stoute","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2005.11.037_bib23","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1471-4922(01)02012-8","article-title":"New World monkey efficacy trials for malaria vaccine development: critical path or detour?","volume":"17","author":"Heppner","year":"2001","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.vaccine.2005.11.037_bib24","doi-asserted-by":"crossref","first-page":"672","DOI":"10.4269\/ajtmh.2002.66.672","article-title":"Anemia in parasite- and recombinant protein-immunized aotus monkeys infected with Plasmodium falciparum","volume":"66","author":"Jones","year":"2002","journal-title":"Am J Trop Med Hyg"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X05011874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X05011874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T20:34:42Z","timestamp":1683318882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X05011874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["S0264410X05011874"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2005.11.037","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}